DNA Repair Communiqué II
In this DNA Repair Communiqué II we delve deeper into the topic...
Read MoreFirst XP-V Patient Treated in CLINUVEL DNA Repair Study
CLINUVEL today announced that the first disease-free subjects have received afamelanotide as...
Read MoreChange of Director's Interest Notice
Melbourne, Australia, 23 March 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...
Read MoreACTH Manufacturing Update
CLINUVEL is progressing scaled manufacturing of adrenocorticotropic hormone (ACTH) under current Good...
Read MoreAfamelanotide in stroke (AIS) – positive preliminary results
CLINUVEL today released positive preliminary results from its pilot study (CUV801) in...
Read MoreChange of Director's Interest Notice
Melbourne, Australia, 02 March 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...
Read MoreCEO letter
On 24 February, the world plunged into instability, initiated by delusional warfare...
Read MoreCLINUVEL Reports Record December Half Year Operating Profit
Melbourne, Australia, 23 February 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...
Read MoreAppendix 4D - ASX Listing Rule 4.2A.3 Half Yearly Report
Melbourne, Australia, 23 February 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...
Read MoreFinancial Results Half Year Ended, 31 December 2021
CLINUVEL PHARMACEUTICALS LTD announced today the financial results for the half year...
Read MoreDNA Repair Communiqué I
This first Communiqué in a series on DNA forms an introductory foundation,...
Read MoreCLINUVEL Expands DNA Repair Program with 2nd DNA Repair Study
CLINUVEL today announced that the first disease-free subjects have received afamelanotide as...
Read MoreAppendix 4C & Activity Report
Melbourne, Australia, 31 January 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...
Read More